Methods were developed for measuring changes in platelet sensitivity to a release-inducing stimulus and in platelet cyclic AMP in fresh whole blood samples from rabbits. These techniques permitted detection of the effects of exogenous and endogenous prostacyclin on circulating platelets. In these methods, rabbit platelets were labeled in vitro by incubation with ["4Clserotonin 
Introduction
Methods were developed for measuring changes in platelet sensitivity to a release-inducing stimulus and in platelet cyclic AMP in fresh whole blood samples from rabbits. These techniques permitted detection of the effects of exogenous and endogenous prostacyclin on circulating platelets. In these methods, rabbit platelets were labeled in vitro by incubation with ["4Clserotonin and VHladenine and then transfused into other rabbits. Release of platelet ['4Cjserotonin by a standard dose of synthetic platelet-activating factor (40 pmol/ml) and the platelet cyclic I3HIAMP levels were then measured in citrated blood from the conscious animals within 2 min of arterial puncture. Bolus intravenous injections of prostacyclin (1-10 nmol/kg) caused concentration-dependent increases in platelet cyclic AMP after 2 min, which decreased '-75% by 5 min, and disappeared after 30 min. Significant inhibition of the platelet release reaction was detected 2 min but not 5 min after injection of 10 nmol of prostacyclin per kilogram. With lower doses, significant enhancement of the release of I'4Clserotonin was observed after 5 min. Similar changes in platelet responsiveness and cyclic I3HIAMP were observed after release of endogenous prostacyclin by intravenous injection of angiotensin II (5 nmol/kg); inhibition of the release of I'4Ciserotonin after 2 min was followed by potentiation after 5 McClenaghan, 1981 , Nature I Lond. I., 292:364-366). Prostacyclin also had a biphasic effect on the release of I'4Ciserotonin when added to citrated blood in vitro, though both the increase in sensitivity to platelet-activating factor and the return of platelet cyclic 13HIAMP towards control values took place more slowly. At all times, addition of platelet-activating factor decreased platelet cyclic I3HJAMP towards but not below the control level observed in the absence of prostacyclin. Our results indicate that although transient increases in platelet cyclic AMP cause an immediate decrease in platelet responsiveness in vivo or in vitro, a period of enhanced platelet sensitivity follows as platelet cyclic AMP falls.
dominantly in the vascular endothelium from the prostaglandin endoperoxide, PGH2 (1, 2) . Its action on platelets results from a receptor-mediated activation of adenylate cyclase and a consequent increase in platelet cyclic AMP (3) (4) (5) . At physiological pH values, PGI2 is spontaneously hydrolyzed to form the inactive compound, 6-keto-PGF1,, (2) , and in vivo >90% of injected PGI2 disappears from the circulation in -2 min (6) . Although it was initially suggested that PGI2 is a circulating hormone that limits platelet aggregation in vivo (7, 8) , studies using several different methods have shown that this is not the case (6, (9) (10) (11) (12) . These observations have led to the current hypothesis that, under physiological conditions, PGI2 acts as a local inhibitor of platelet aggregation without affecting platelet function in the general circulation. However, certain pharmacological agonists, including angiotensin 11 (6, 13, 14) , and some potential drugs that modify platelet function, such as nafazatrom (15, 16), can stimulate or enhance the release of PGI2 into the circulation. In addition, inhibitors of thromboxane synthetase may re-orientate the metabolism of PGH2 formed in platelets towards the synthesis of PGI2 by endothelial cells (16) (17) (18) was diluted to 0.1 mM with 0.154 M NaCi that contained 3.5 mg of crystallized bovine serum albumin/ml and 5 mM Hepes, pH 7.4. Further dilutions were made with 0.154 M NaCi that contained 3.5 mg of crystallized rabbit albumin/ml, just before their use. PGI2 was a gift from Dr. J. Pike of Upjohn Co. (Kalamazoo, MI). Stock solutions of PGI2 were prepared at a concentration of I mM in 9.4 mM Na2CO3, stored in 0.02-ml aliquots at -550C, and diluted just before use in 0.139 M NaCl that contained 9.4 mM Na2CO3. Male New Zealand white rabbits (2.2-3.0 kg) were used in this study.
Preparation oflabeled platelets for injection into rabbits. Blood was obtained by cannulation of the carotid artery from rabbits that had been anesthetized with pentobarbitol and was mixed with 0.175 vol of acid citrate dextrose (ACD) anticoagulant (19) . Platelet-rich plasma was prepared by centrifuging the blood twice at 250 g for 15 min. This material was centrifuged for 10 min at 3,500 g and the platelets from each rabbit were resuspended in 10 ml of ACD plasma. This procedure was repeated to remove residual red cells and the final suspension, containing 2.5 X 109 platelets/ml, was incubated for 90 min at room temperature with 4 In experiments in which the effects of injection of PGI2 or angiotensin II were studied, blood was taken at intervals from successively more proximal segments of the central arteries of the ears of conscious rabbits into 0.1 vol of 3.8% (wt/vol) Na3 citrate.2H20 (final volume usually 4.5 ml). These blood samples were subdivided as follows: two 0.4-ml samples were stirred without and two with PAF (40 pmol/ml) for 0.5 min before the addition of formaldehyde/EDTA and measurement of the ["Ciserotonin released, as described below; three 0.1-ml samples were lysed in 0.6 ml of H20 for determination of the total blood 14C; three 0.8-ml samples were each extracted with 0. (20) . Three 0.1-ml blood samples were lysed in 0.6 ml of H20 and mixed with 0.2 ml of 1 M ascorbic acid, followed by 0.2 ml of 5 M HC104. After 10 min at 00C, these samples were centrifuged at 12,000 g for 2 min. The supernatant was partially neutralized by addition of 0.08 ml of 10 M KOH, and after a further 10 min at 00C was centrifuged again to remove KC104. The Measurement ofthe purity ofcyclic [3HJAMP isolatedfrom labeled platelets in whole blood. Samples of citrated blood were taken from a rabbit that had been transfused with labeled platelets. The 3H-and "C-labeled cyclic nucleotides were isolated as described above, acidified with HCG, and re-chromatographed on Dowex 50 to remove phosphate. The labeled cyclic AMP was dissolved in 0.1 ml of I mM cyclic AMP; 5 Ml was counted for 3H and '4C, and 45-;MI samples were incubated for 30 min at 30°C with and without 0.2 U of cyclic nucleotide phosphodiesterase [in 5 Mil of 100 mM N-tris(hydroxymethyl)-methyl-2-aminoethanesulfonic acid (Na+ salt, pH 7.5), 40 mM MgSO4, and 2.5 mM EDTAJ. These incubations were terminated by boiling, and cyclic AMP and AMP were separated by thin-layer chromatography on cellulose using n-butanol/acetone/acetic acid/14.8 M NH3/H20 (90: 30:20:1:60, by volume). Cyclic AMP and AMP were eluted from the cellulose with H20 and counted for 3H and 14C. The purity of the material isolated as cyclic [3H]AMP by the standard method was calculated from the decrease (if any) in the ratio of 3H to "4C after its further purification and conversion to AMP.
Determination of the cellular distribution of3H and '"C in blood from rabbits injected with labeled platelets. Blood samples (10 ml) from rabbits that had been injected with labeled platelets were taken into ACD anticoagulant and diluted with 3 vol of solution containing 13 mM Na3 citrate, 5 mM dextrose, and 135 mM NaCI (pH 6.5). Platelets and lymphocytes were isolated from red cells and granulocytes by Ficoll-Hypaque density centrifugation (23) and separated by centrifugation through a discontinuous sucrose gradient (24) . The platelets present in the red cell-granulocyte, lymphocyte, and platelet fractions were counted in a hemacytometer after dilution with 1% ammonium oxalate (22). The 3H and "4C present in these fractions were determined; e.g., Fig. 1 B) . Simultaneous measurement of the release of platelet ATP using firefly luciferin-luciferase (Fig. 1, C and D) showed that the behavior of the total platelet population in the blood samples was not significantly different from that of labeled platelets with respect to induction of the release reaction by PAF (EC1O = 46±4 pmol/ml, four experiments; P > 0.7) or its inhibition by PG!2 (ICK0 = 4.6±0.1 pmol/ml, four experiments; P > 0.5). Analysis of the variance of the results shown in Fig. 1 , B and D, indicated that measurement of the release of ['4Clserotonin was less subject to error than measurement of the release of ATP (P < 0.025). Platelets in native blood showed the same sensitivity to PG!2 with respect to inhibition of the release of ['4C]serotonin by PAF (IC50 = 4.6±0.9 pmol/ml, four experiments; P > 0.4). These results indicated that a PAF concentration of 40 pmol/ml was suitable for detection of the inhibitory action of PGI2 on the release of ['4C]serotonin in fresh whole blood samples.
When blood samples were taken 10 min after transfusion of labeled platelets into rabbits, the '4C present indicated that all the injected platelets were in the circulation (assuming a value of 65 ml of blood per kilogram). Moreover, blood '4C did not decrease significantly for at least 2 h (five rabbits). The release of platelet ['4C]serotonin by PAF remained constant in blood samples taken throughout this period (Fig. 2 B) . (means±SE) from 6 to 10 rabbits are shown. Statistical significance is indicated by * (P < 0.05) and ** (P < 0.01).
to blood taken at this time. However, after 5 min, the release of ['4C]serotonin by PAF was enhanced, although platelet cyclic [3H]AMP was still above control levels, as observed after injection of PGI2. The results from 10 rabbits are summarized in Fig. 5 . Both the increases in platelet cyclic [3H]AMP and the inhibition and potentiation of platelet responsiveness after 2 and 5 min, respectively, were statistically significant. Control values for platelet cyclic [3HJAMP and platelet responsiveness were re-established by 30 min, at which time blood PGI2 had also returned to basal levels (6) . None of these effects were observed after injection of saline into rabbits (e.g., Fig. 4) .
Potentiation of the platelet release reaction by addition of PGI2 to citrated whole blood; relationship to platelet cyclic [3HIAMP. These experiments were undertaken to determine whether the stimulatory effects of PGI2 on platelet responsiveness in vivo could be reproduced in vitro. The PAF concentration used to induce release of ['4C]serotonin was decreased to 20 pmol/ml to facilitate detection of any potentiation of the secretory response. When PAF was added after incubation of the blood with PGI2 for 0.5 min, the release of platelet ['4C]serotonin was significantly inhibited by .2 pmol of PGI2/ ml, whereas when PAF was added 30 min after addition of 0.5-4.0 pmol of PGI2/ml, the amount of ['4C]serotonin released was significantly greater than the controls (Fig. 6 A) . At least 15 min incubation with PGI2 was required for the development of enhanced sensitivity to PAF in whole blood in vitro. Thus, the results show that the enhanced platelet reactivity observed after injection of PGI2 into rabbits is attributable to the action of PGI2 on blood components only. When the release of both [14C] serotonin and ATP by 15-30 pmol of PAF/ml was measured with and without the prior addition of 4 pmol of PGI2/ml (results not shown), potentiation of ATP secretion was difficult to demonstrate in individual experiments because of the error inherent in measuring ATP, but was significant overall (P = 0.01 5, analysis of variance in seven experiments).
Moreover, no significant difference was observed between the enhancement of secretion detected by the two methods (P = 0.58, analysis of variance). This indicates that the potentiation of secretion by PGI2, like inhibition, reflects an effect of PGI2 on the whole platelet population. The increase in platelet cyclic [3H]AMP measured 0.5 min after addition of 0.5-4.0 pmol of PGI2/ml to citrated blood was roughly proportional to the PGI2 concentration added. After 30 min, the increases in cyclic [3H]AMP in the blood samples were substantially lower but still significant with .2 pmol of PGI2/ml (P < 0.05) (Fig. 6 B) . Thus, potentiation of the platelet release reaction by PGI2 was associated with increased levels of cyclic AMP at the time of addition of PAF. Since PAF inhibits cyclic AMP formation in intact rabbit platelets (26) , the effects of incubation of blood for 0.5 min Time after PGI2 addition (min) 40) and the synthesis of platelet polyphosphoinositides (41) are probably enhanced by cyclic AMP and so could be involved. Possible significance of the enhancement of the platelet release reaction by PGI2 in the rabbit. Although enhanced platelet sensitivity to aggregating agents does not so far appear to have been observed during or after continuous infusion of PG12 into rabbits (27), there have been several reports of a rebound in platelet responsiveness associated with prolonged infusions of PGI2 into man (29, 31, 32) . As the latter studies were carried out with platelet-rich plasma prepared at various times after venepuncture, they cannot be directly compared with ours, but the long delay before the appearance of potentiated responses suggests that the mechanism responsible may differ from that operating in our experiments. More obviously relevant to our results are reports that addition of very low concentrations of PGT2 can stimulate aggregation of human platelets (42) , and that the functional viability of washed platelets is greatly prolonged when they are washed in the presence of PGI2 (43) . All these effects of PGI2 on the responsiveness of platelets to aggregating agents can be distinguished from desensitization of platelets to the inhibitory action of PGI2, which also occurred during prolonged infusion of the compound into man (28, 31, 32) , but which appears to be relatively receptor-specific (31). However, no evidence for desensitization of the cyclic AMP response to PGI2 was obtained in the present study. It is possible that the enhanced platelet responsiveness after exposure to PGI2, which we have detected for the first time in an experimental animal, has a physiological role. Thus, the local production of PGI2 could not only limit platelet deposition at sites of vascular injury, but could also help to maintain or enhance the subsequent responsiveness of platelets that are not irreversibly lost at such sites.
